药捷安康 ：通过一般授权配售新H股募资约1.95亿港元 核心产品研发及一般企业用途

Group 1 - The company,药捷安康, announced a financing plan through the placement of new H-shares, issuing 2,100,000 shares to raise approximately HKD 195 million, with net proceeds expected to be around HKD 190 million after expenses [1] - The placement price of HKD 92.85 represents an approximately 18.0% discount to the closing price of HKD 113.20 on the previous trading day and an 18.3% discount to the average closing price of HKD 113.66 over the last five trading days [1] - The newly issued shares will account for about 0.53% of the existing issued share capital and will also represent approximately 0.53% of the enlarged share capital post-issuance [1] Group 2 - The funds raised will primarily be allocated to the clinical trials of the core product Tinengotinib, as well as for the development of other products, operational funding, and general corporate purposes [1] - The issuance is conducted under a general authorization granted by the shareholders' meeting and is expected to be completed by January 21, 2026 [1] - The company focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, positioning itself as a clinical demand-driven innovative pharmaceutical company [1]